Tetraphase Pharmaceuticals, Inc. (TTPH) Cut to Sell at Zacks Investment Research
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Saturday.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Several other analysts have also issued reports on the company. Stifel Nicolaus upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the stock from $8.00 to $15.00 in a report on Wednesday, July 26th. HC Wainwright initiated coverage on Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They set a “buy” rating and a $15.00 target price on the stock. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Sunday, September 17th. BidaskClub upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. Finally, BMO Capital Markets restated an “outperform” rating and issued a $13.00 price objective (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, July 26th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $12.96.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $6.36 on Friday.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.63). The firm had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The company’s revenue was up 355.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.58) earnings per share. research analysts anticipate that Tetraphase Pharmaceuticals will post -2.87 EPS for the current fiscal year.
In other news, insider Jacques Dumas sold 8,750 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total value of $52,762.50. Following the transaction, the insider now owns 8,750 shares of the company’s stock, valued at $52,762.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 33,405 shares of company stock worth $199,691 in the last ninety days. 5.50% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. grew its position in shares of Tetraphase Pharmaceuticals by 6.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 128,807 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 7,866 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Tetraphase Pharmaceuticals by 16.4% in the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after purchasing an additional 230,420 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Tetraphase Pharmaceuticals by 3.4% in the first quarter. Bank of New York Mellon Corp now owns 187,897 shares of the biopharmaceutical company’s stock valued at $1,726,000 after purchasing an additional 6,114 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Tetraphase Pharmaceuticals by 17.0% in the first quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock valued at $2,880,000 after purchasing an additional 45,554 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Tetraphase Pharmaceuticals by 180.4% in the first quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 408,078 shares during the last quarter. 40.92% of the stock is currently owned by institutional investors.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.